author-photo

David M. Nanus

Cornell University
Memorial Sloan Kettering Cancer Center
NewYork–Presbyterian Hospital

454

Papers

19527

Citations

Citation Trend

Filter By

Papers (310) Sort By

Journal Conference Others

A phase I/II dose-escalation study of fractionated and multiple dose 225Ac-J591 for progressive metastatic castration-resistant prostate cancer (mCRPC).

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Baseline and post-treatment circulating tumor cell (CTC) counts with prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy (TRT) in men with metastatic castration-resistant prostate cancer (mCRPC).

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer.

2021 Nature Communications
Show All
- Source
- Cite
- Save
Citations (2)
Prostate-Specific Membrane Antigen Uptake and Survival in Metastatic Castration-Resistant Prostate Cancer

2021 Frontiers in Oncology
Show All
- Source
- Cite
- Save
Citations (4)
MP24-05 LONG-TERM FOLLOW-UP AND PROGNOSTIC FACTOR ANALYSIS IN MEN WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) WHO RECEIVE PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA)-TARGETED LUTETIUM-177 (177LU)

2021 The Journal of Urology
Show All
- Source
- Cite
- Save
Citations (0)
Phase I trial of apalutamide (Apa) with abiraterone acetate (AA) plus prednisone (P) and docetaxel (Doce) in patients with metastatic castration-resistant prostate cancer (mCRPC).

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Eliciting the Social Determinants of Cancer Prevention and Control in the Catchment of an Urban Cancer Center

2021 Ethnicity & Disease
Show All
- Source
- Cite
- Save
Citations (0)
AR-V7 exhibits non-canonical mechanisms of nuclear import and chromatin engagement in Castrate-Resistant Prostate Cancer

2021 bioRxiv
Show All
- Source
- Cite
- Save
Citations (0)
Imaging expression of prostate-specific membrane antigen and response to PSMA-targeted β-emitting radionuclide therapies in metastatic castration-resistant prostate cancer.

2021 The Prostate
Show All
- Source
- Cite
- Save
Citations (4)
629P Patient-reported outcomes in prostate cancer patients receiving PSMA-targeted radionuclide therapy

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)